Developer docs
API playgroundTry for free, no card

Search company profiles

Kymos Pharma Services

Full company profile

uuid000cwj6

Namestring
Kymos Pharma Services
Legal namestring
KYMOS GROUP, S.L.
Websiteurl
kymos.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Kymos Pharma Services is a Barcelona-headquartered Contract Research Organization (CRO) founded in 2001, providing GLP-certified bioanalytical and GMP-certified CMC (Chemistry, Manufacturing and Controls) services to pharmaceutical, biotechnology, veterinary, cosmetic, and nutraceutical clients. The company operates four European laboratories — Kymos Spain (Cerdanyola del Vallès), Pharmaprogress in Italy, Prolytic in Germany, and the recently acquired Particle Analytical in Denmark — and added a representative office in Seoul, South Korea in December 2025. Under the 2024-established parent KYMOS GROUP, S.L., the group is structured to deliver analytical services across the full drug development lifecycle, from preclinical research through commercial manufacturing and regulatory submission.

The service portfolio is organized along two axes: development phase (Pre-Clinical & Clinical Services, Solid State Analysis, CMC Analysis & Quality Control) and molecule modality (Small Molecules, Biologics and Biosimilars, TIDES/Oligonucleotides & Peptides, and Cell & Gene Therapies). Capabilities include bioequivalence studies, pharmacokinetics, biomarker analysis, immunogenicity testing, biosimilar comparability, viral vector characterization, lipid nanoparticle testing, stability studies, and the newer solid-state/particle analysis line. The group is inspected by the FDA, EMA, and ANVISA, holds ISO 27001 and EU NIS 2 Directive compliance, and is led by founder/Chairman Joan Puig Corcoy and CEO Joan Puig de Dou.

The business model is project-based professional services, priced via custom quotations tied to scope, complexity, and turnaround, with multi-year contracts typical of regulated drug development engagements. Go-to-market is direct enterprise sales through scientific relationship management and presence at major industry events (CPHI, BIO-Europe, BioSpain, European Bioanalysis Forum). Named enterprise clients include Celltrion, PharmaMar, HELM, Combino Pharm, Exeltis, and Omeicos Therapeutics, with revenue derived entirely from contract research fees. No external funding rounds or disclosed financials are available, and the company is privately held.

Short descriptiontext

Kymos Pharma Services is a Barcelona-headquartered analytical CRO providing GLP/GMP-certified bioanalysis and CMC services across small molecules, biologics, TIDES, and cell & gene therapies to pharmaceutical, biotech, and specialty chemistry clients globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioanalytical services, CMC testing services, contract research organization, pharmaceutical quality control, GMP analytical testing
Industry6 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)
SECONDARYHLAGADAC
Release Testing & Batch Certification (QC)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
NAICS code3 codes
  • Testing Laboratories and Services54138
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code3 codes
  • Services-Testing Laboratories8734
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Contract Research Organization (CRO) Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Project-based contract research services for bioanalysis and CMC testing throughout the product lifecycle, from early R&D to manufacturing and commercialization.

kymos.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Services are priced based on project scope, complexity, and turnaround time requirements. Clients receive detailed quotations before work commencement.

kymos.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Prolytic
Description

Kymos Germany subsidiary specializing in bioanalytical and CMC services

kymos.com
+2 more records
Core offering1 text field

Kymos is an analytical Contract Research Organization (CRO) providing GLP-certified bioanalytical services and GMP-certified CMC and quality control testing for pharmaceutical, biotechnology, veterinary, fine chemistry, cosmetic, and nutraceutical sponsors. Offerings cover the full drug development lifecycle, from preclinical and clinical bioanalysis through commercial release testing, across multiple molecule classes including small molecules, biologics and biosimilars, TIDES (oligonucleotides and peptides), and cell & gene therapies, with additional solid-state analysis and characterization expertise.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Kymos Group is an analytical Contract Research Organization (CRO) providing bioanalytical and CMC (Chemistry, Manufacturing and Controls) services across four European laboratories (Spain, Italy, Germany, and Denmark) and a South Korea office. The company operates as a unified service portfolio organized by molecule type (Small Molecules, Biologics and Biosimilars, TIDES/Oligo & Peptides, Cell & Gene Therapies) and service phase (Pre-Clinical & Clinical Services, Solid State Analysis, CMC Analysis & Quality Control). Services cover the entire drug product lifecycle from early research and development through manufacturing and commercialization, serving the pharmaceutical, biotechnology, veterinary, fine chemistry, cosmetic, and nutraceutical industries. The group is GLP- and GMP-certified and has been inspected by EMA, ANVISA, and FDA.

Product and service7 records
1Pre-Clinical & Clinical Bioanalysis Services
CategoryBioanalytical Services
Description

GLP-compliant bioanalytical method development, validation, and sample analysis to support preclinical and clinical studies for pharmaceutical and biotechnology sponsors developing small molecules, biologics/biosimilars, TIDES, and cell & gene therapies.

2Solid State Analysis
CategoryAnalytical Characterization Services
Description

Characterization of the solid-state properties of drug substances and drug products for pharmaceutical clients, addressing questions of polymorphism, crystal form, and physical stability that are relevant to formulation and regulatory submissions.

3CMC Analysis & Quality Control
CategoryCMC and Quality Control Services
Description

GMP-certified CMC testing, release testing, stability studies, and quality control support for pharmaceutical, biotechnology, veterinary, cosmetic, nutraceutical, and fine chemistry clients across the product lifecycle.

4Small Molecules Services
CategoryMolecule-Specific Services
Description

Bioanalytical and CMC services tailored to small molecule drug development, including method development, validation, and routine testing for pharmaceutical sponsors.

5Biologics and Biosimilars Services
CategoryMolecule-Specific Services
Description

Bioanalytical and characterization testing for biologics and biosimilars, addressing the analytical needs of large molecule drug development including comparability and biosimilarity assessments.

6TIDES (Oligonucleotides and Peptides) Services
CategoryMolecule-Specific Services
Description

Bioanalytical and CMC services for TIDES, covering oligonucleotides and peptides, including method development, validation, and testing for sponsors developing these therapeutic modalities.

7Cell & Gene Therapies Services
CategoryAdvanced Therapy Services
Description

Bioanalytical and characterization testing for cell and gene therapy programs, providing specialized analytical support for advanced therapy medicinal products (ATMPs) and viral vector characterization.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-01
Description

Kymos acquired Particle Analytical (Denmark) to strengthen particle analysis and solid state characterization services across Europe, expanding the group's capabilities in solid state analysis services.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Eurofins operates one of the largest global bioanalytical and CMC testing networks, including small-molecule and biologics LC-MS and immunoassay work. It competes head-to-head with Kymos on regulated bioanalysis, immunogenicity, and biosimilar comparability for pharma and biotech sponsors.

TypeBroad incumbent
Description

Labcorp's drug development business (formerly Covance) provides central labs, bioanalytical, and CMC services globally. It overlaps Kymos's central-lab and bioanalysis capabilities but typically as part of bundled clinical-trial service offerings to large pharma.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO with end-to-end clinical, bioanalytical, and real-world evidence services. While not a pure analytical specialist, it bids against Kymos for bioanalytical and central-lab work embedded in enterprise clinical packages.

TypeBroad incumbent
Description

Intertek provides GMP pharmaceutical and biopharmaceutical testing, including CMC, release testing, and particle analysis services globally. Its release-testing and particle-characterization capabilities directly overlap the CMC and Particle Analytical (Denmark) parts of Kymos's portfolio.

TypeDirect peer
Description

Pharmaron operates a fully integrated CRO/CDMO platform with bioanalytical labs in the US, UK, and China covering small molecules, biologics, and oligonucleotides. Its TIDES/bioanalytical offering and multi-country lab model put it in direct competition for the same enterprise accounts as Kymos.

TypeDirect peer
Description

Celerion is a specialist early-phase clinical and bioanalytical CRO with deep expertise in PK/PD, bioequivalence, and biomarker analysis. It directly overlaps Kymos's pre-clinical and clinical bioanalysis service lines for small molecules and biologics.

TypeBroad incumbent
Description

WuXi AppTec is a global CRO/CDMO with bioanalytical and CMC services across small molecules, biologics, and advanced therapies. Although China-headquartered, its broad analytical platform competes with Kymos for European and US pharma outsourcing, particularly for biologics and ATMP work.

TypeBroad incumbent
Description

Charles River is a global CRO offering bioanalytical, safety assessment, and manufacturing services across small molecules and biologics. It competes with Kymos on regulated analytical work but as part of a much broader discovery-through-manufacturing portfolio rather than as an analytical specialist.

TypeDirect peer
Description

Frontage offers bioanalytical, CMC, and biologics services across US and China labs, including integrated drug development support. Its integrated analytical-and-CMC model for small molecules and biologics is highly comparable to Kymos's full-lifecycle service catalog.

TypeDirect peer
Description

SGS provides analytical, bioanalytical, and CMC testing services across a global laboratory footprint, including biologics characterization and clinical-trial-supporting assays. Its scope and multi-modality positioning closely mirror Kymos's bioanalysis-plus-CMC value proposition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kymos Pharma Services

Contract Research Organization (CRO) Serviceskymos.com

Kymos Pharma Services is a Barcelona-headquartered analytical CRO providing GLP/GMP-certified bioanalysis and CMC services across small molecules, biologics, TIDES, and cell & gene therapies to pharmaceutical, biotech, and specialty chemistry clients globally.

What Kymos Pharma Services does

Kymos Pharma Services is a Barcelona-headquartered Contract Research Organization (CRO) founded in 2001, providing GLP-certified bioanalytical and GMP-certified CMC (Chemistry, Manufacturing and Controls) services to pharmaceutical, biotechnology, veterinary, cosmetic, and nutraceutical clients. The company operates four European laboratories — Kymos Spain (Cerdanyola del Vallès), Pharmaprogress in Italy, Prolytic in Germany, and the recently acquired Particle Analytical in Denmark — and added a representative office in Seoul, South Korea in December 2025. Under the 2024-established parent KYMOS GROUP, S.L., the group is structured to deliver analytical services across the full drug development lifecycle, from preclinical research through commercial manufacturing and regulatory submission.

The service portfolio is organized along two axes: development phase (Pre-Clinical & Clinical Services, Solid State Analysis, CMC Analysis & Quality Control) and molecule modality (Small Molecules, Biologics and Biosimilars, TIDES/Oligonucleotides & Peptides, and Cell & Gene Therapies). Capabilities include bioequivalence studies, pharmacokinetics, biomarker analysis, immunogenicity testing, biosimilar comparability, viral vector characterization, lipid nanoparticle testing, stability studies, and the newer solid-state/particle analysis line. The group is inspected by the FDA, EMA, and ANVISA, holds ISO 27001 and EU NIS 2 Directive compliance, and is led by founder/Chairman Joan Puig Corcoy and CEO Joan Puig de Dou.

The business model is project-based professional services, priced via custom quotations tied to scope, complexity, and turnaround, with multi-year contracts typical of regulated drug development engagements. Go-to-market is direct enterprise sales through scientific relationship management and presence at major industry events (CPHI, BIO-Europe, BioSpain, European Bioanalysis Forum). Named enterprise clients include Celltrion, PharmaMar, HELM, Combino Pharm, Exeltis, and Omeicos Therapeutics, with revenue derived entirely from contract research fees. No external funding rounds or disclosed financials are available, and the company is privately held.

Kymos Pharma Services firmographics

Firmographics
Name
Kymos Pharma Services
Legal name
KYMOS GROUP, S.L.
Website
https://kymos.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
251–500 employees
Short description
Kymos Pharma Services is a Barcelona-headquartered analytical CRO providing GLP/GMP-certified bioanalysis and CMC services across small molecules, biologics, TIDES, and cell & gene therapies to pharmaceutical, biotech, and specialty chemistry clients globally.
Ownership category
akta.pro rank

Kymos Pharma Services industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Testing Laboratories and Services (54138), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)
SECONDARYHLAGADAC
Release Testing & Batch Certification (QC)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)

Keywords

  • Bioanalytical services
  • CMC testing services
  • Contract research organization
  • Pharmaceutical quality control
  • GMP analytical testing

Where Kymos Pharma Services is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Offices6 records

Markets served

Kymos Pharma Services business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: Project-based contract research services for bioanalysis and CMC testing throughout the product lifecycle, from early R&D to manufacturing and commercialization.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Kymos Pharma Services product offering

Product offering

Core offering

Kymos is an analytical Contract Research Organization (CRO) providing GLP-certified bioanalytical services and GMP-certified CMC and quality control testing for pharmaceutical, biotechnology, veterinary, fine chemistry, cosmetic, and nutraceutical sponsors. Offerings cover the full drug development lifecycle, from preclinical and clinical bioanalysis through commercial release testing, across multiple molecule classes including small molecules, biologics and biosimilars, TIDES (oligonucleotides and peptides), and cell & gene therapies, with additional solid-state analysis and characterization expertise.

Product overview

Kymos Group is an analytical Contract Research Organization (CRO) providing bioanalytical and CMC (Chemistry, Manufacturing and Controls) services across four European laboratories (Spain, Italy, Germany, and Denmark) and a South Korea office. The company operates as a unified service portfolio organized by molecule type (Small Molecules, Biologics and Biosimilars, TIDES/Oligo & Peptides, Cell & Gene Therapies) and service phase (Pre-Clinical & Clinical Services, Solid State Analysis, CMC Analysis & Quality Control). Services cover the entire drug product lifecycle from early research and development through manufacturing and commercialization, serving the pharmaceutical, biotechnology, veterinary, fine chemistry, cosmetic, and nutraceutical industries. The group is GLP- and GMP-certified and has been inspected by EMA, ANVISA, and FDA.

Differentiator

Problem solved

Functional benefit

Brands

  • Prolytic: Kymos Germany subsidiary specializing in bioanalytical and CMC services
  • Pharmaprogress
  • Particle Analytical

Products and services

  • Pre-Clinical & Clinical Bioanalysis Services GLP-compliant bioanalytical method development, validation, and sample analysis to support preclinical and clinical studies for pharmaceutical and biotechnology sponsors developing small molecules, biologics/biosimilars, TIDES, and cell & gene therapies.
  • Solid State Analysis Characterization of the solid-state properties of drug substances and drug products for pharmaceutical clients, addressing questions of polymorphism, crystal form, and physical stability that are relevant to formulation and regulatory submissions.
  • CMC Analysis & Quality Control GMP-certified CMC testing, release testing, stability studies, and quality control support for pharmaceutical, biotechnology, veterinary, cosmetic, nutraceutical, and fine chemistry clients across the product lifecycle.
  • Small Molecules Services Bioanalytical and CMC services tailored to small molecule drug development, including method development, validation, and routine testing for pharmaceutical sponsors.
  • Biologics and Biosimilars Services Bioanalytical and characterization testing for biologics and biosimilars, addressing the analytical needs of large molecule drug development including comparability and biosimilarity assessments.
  • TIDES (Oligonucleotides and Peptides) Services Bioanalytical and CMC services for TIDES, covering oligonucleotides and peptides, including method development, validation, and testing for sponsors developing these therapeutic modalities.
  • Cell & Gene Therapies Services Bioanalytical and characterization testing for cell and gene therapy programs, providing specialized analytical support for advanced therapy medicinal products (ATMPs) and viral vector characterization.

Companies that use Kymos Pharma Services

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Kymos Pharma Services technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Kymos Pharma Services partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Particle AnalyticalcoreStrategic or Co-development Partner · 1 February 2026Kymos acquired Particle Analytical (Denmark) to strengthen particle analysis and solid state characterization services across Europe, expanding the group's capabilities in solid state analysis services.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Kymos Pharma Services competitors and assessment

Company assessment

Direct peers

  • Eurofins Bioanalytical Services: Eurofins operates one of the largest global bioanalytical and CMC testing networks, including small-molecule and biologics LC-MS and immunoassay work. It competes head-to-head with Kymos on regulated bioanalysis, immunogenicity, and biosimilar comparability for pharma and biotech sponsors.
  • Pharmaron: Pharmaron operates a fully integrated CRO/CDMO platform with bioanalytical labs in the US, UK, and China covering small molecules, biologics, and oligonucleotides. Its TIDES/bioanalytical offering and multi-country lab model put it in direct competition for the same enterprise accounts as Kymos.
  • Celerion: Celerion is a specialist early-phase clinical and bioanalytical CRO with deep expertise in PK/PD, bioequivalence, and biomarker analysis. It directly overlaps Kymos's pre-clinical and clinical bioanalysis service lines for small molecules and biologics.
  • Frontage Laboratories: Frontage offers bioanalytical, CMC, and biologics services across US and China labs, including integrated drug development support. Its integrated analytical-and-CMC model for small molecules and biologics is highly comparable to Kymos's full-lifecycle service catalog.
  • SGS Health Sciences: SGS provides analytical, bioanalytical, and CMC testing services across a global laboratory footprint, including biologics characterization and clinical-trial-supporting assays. Its scope and multi-modality positioning closely mirror Kymos's bioanalysis-plus-CMC value proposition.

Broad incumbents

  • Labcorp Drug Development: Labcorp's drug development business (formerly Covance) provides central labs, bioanalytical, and CMC services globally. It overlaps Kymos's central-lab and bioanalysis capabilities but typically as part of bundled clinical-trial service offerings to large pharma.
  • IQVIA: IQVIA is the world's largest CRO with end-to-end clinical, bioanalytical, and real-world evidence services. While not a pure analytical specialist, it bids against Kymos for bioanalytical and central-lab work embedded in enterprise clinical packages.
  • Intertek Pharmaceutical Services: Intertek provides GMP pharmaceutical and biopharmaceutical testing, including CMC, release testing, and particle analysis services globally. Its release-testing and particle-characterization capabilities directly overlap the CMC and Particle Analytical (Denmark) parts of Kymos's portfolio.
  • WuXi AppTec / WuXi STA: WuXi AppTec is a global CRO/CDMO with bioanalytical and CMC services across small molecules, biologics, and advanced therapies. Although China-headquartered, its broad analytical platform competes with Kymos for European and US pharma outsourcing, particularly for biologics and ATMP work.
  • Charles River Laboratories: Charles River is a global CRO offering bioanalytical, safety assessment, and manufacturing services across small molecules and biologics. It competes with Kymos on regulated analytical work but as part of a much broader discovery-through-manufacturing portfolio rather than as an analytical specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Kymos Pharma Services social profiles

Digital presence

Kymos Pharma Services compliance and trust

Trust signal

Compliance4 records

Kymos Pharma Services financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kymos Pharma Services leadership team

Management profile

Number of profiles

Profiles6 records

Kymos Pharma Services subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Kymos Pharma Services funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kymos Pharma Services M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kymos Pharma Services

What does Kymos Pharma Services do?

Kymos is an analytical Contract Research Organization (CRO) providing GLP-certified bioanalytical services and GMP-certified CMC and quality control testing for pharmaceutical, biotechnology, veterinary, fine chemistry, cosmetic, and nutraceutical sponsors. Offerings cover the full drug development lifecycle, from preclinical and clinical bioanalysis through commercial release testing, across multiple molecule classes including small molecules, biologics and biosimilars, TIDES (oligonucleotides and peptides), and cell & gene therapies, with additional solid-state analysis and characterization expertise.

Is Kymos Pharma Services a public or private company?

Kymos Pharma Services is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Kymos Pharma Services founded?

Kymos Pharma Services was founded in 2001. It employs 251 to 500 people.

Where is Kymos Pharma Services based?

Kymos Pharma Services is headquartered in Barcelona, Spain, in the Europe region.

How does Kymos Pharma Services make money?

One revenue line is on record: contract Research Services.

Who are Kymos Pharma Services's main competitors?

Direct peers on record are Eurofins Bioanalytical Services, Pharmaron, Celerion, Frontage Laboratories and SGS Health Sciences. Broad incumbents are Labcorp Drug Development, IQVIA, Intertek Pharmaceutical Services, WuXi AppTec / WuXi STA and Charles River Laboratories.

Does Kymos Pharma Services have an API?

No public API is recorded for Kymos Pharma Services.

What industry is Kymos Pharma Services in?

Kymos Pharma Services's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGADAA, Bioanalytical Testing (PK/ADA/NAb). Its NAICS code is 54138 and its SIC code is 8734.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals